Updates are available Correction dated 2023-05-22
Click to view Correction: https://doi.org/10.1186/s12889-023-15867-6
-
Authors
Graupera, Isabel
Thiele, Maja
Ma, Ann T.
Serra-Burriel, Miquel
Pich, Judit
Fabrellas, Núria
Caballeria, Llorenç
de Knegt, Robert J.
Grgurevic, Ivica
Reichert, Mathias
Roulot, Dominique
Schattenberg, Jörn M.
Pericas, Juan M.
Angeli, Paolo
Tsochatzis, Emmanuel A.
Guha, Indra Neil
Garcia-Retortillo, Montserrat
Morillas, Rosa M.
Hernández, Rosario
Hoyo, Jordi
Fuentes, Matilde
Madir, Anita
Juanola, Adrià
Soria, Anna
Juan, Marta
Carol, Marta
Diaz, Alba
Detlefsen, Sönke
Toran, Pere
Pera, Guillem
Fournier, Céline
Llorca, Anne
Newsome, Phillip N.
Manns, Michael
de Koning, Harry J.
Serra-Burriel, Feliu
Cucchietti, Fernando
Arslanow, Anita
Korenjak, Marko
van Kleef, Laurens
Falcó, Josep Lluis
Kamath, Patrick S.
Karlsen, Tom H.
Castera, Laurent
Lammert, Frank
Krag, Aleksander
Ginès, Pere https://orcid.org/0000-0003-4657-4504
,
Alvarez, Marifé
Andersen, Peter
Angeli, Paolo
Ardèvol, Alba
Arslanow, Anita
Beggiato, Luca
Abdesselam, Zahia Ben
Bennett, Lucy
Boutouria, Bajiha
Brocca, Alessandra
Broquetas, M. Teresa
Caballeria, Llorenc
Calvino, Valeria
Camacho, Judith
Capdevila, Aura
Carol, Marta
Castera, Laurent
Cervera, Marta
Cucchietti, Fernando
de Fuentes, Anna
de Knegt, Rob
Detlefsen, Sonke
Diaz, Alba
Bande, José Diéguez
Esnault, Vanessa
Fabrellas, Núria
Falco, Josep lluis
Fernández, Rosa
Fournier, Celine
Fuentes, Matilde
Galle, Peter
García, Edgar
García-Retortillo, Montserrat
Garrido, Esther
Ginès, Pere
Medina, Rosa Gordillo
Gratacós-Gines, Jordi
Graupera, Isabel
Grgurevic, Ivica
Guha, Indra Neil
Guix, Eva
Harris, Rebecca
Boluda, Elena Hernández
Hernández-Ibañez, Rosario
Hoyo, Jordi
Ikram, Arfan
Incicco, Simone
Israelsen, Mads
Juan, Marta
Juanola, Adria
Kaiser, Ralf
Kamath, Patrick S.
Karlsen, Tom H.
Kjærgaard, Maria
de Koning, Harry J.
Korenjak, Marko
Krag, Aleksander
Hansen, Johanne Kragh
Krawczyk, Marcin
Lambert, Irina
Lammert, Frank
Laboulaye, Philippe
Sørensen, Simon Langkjær
Laserna-Jiménez, Cristina
Pi, Sonia Lazaro
Ledain, Elsa
Levy, Vincent
Londoño, Vanessa
Loyer, Guirec
Llorca, Anne
Ma, Ann T.
Madir, Anita
Manns, Michael
Marshall, Denise
Martí, M. Lluïsa
Martínez, Sara
Sala, Ricard Martínez
Font, Roser Masa
Jensen, Jane Møller
Morillas, Rosa M.
Muñoz, Laura
Nadal, Ruth
Napoleone, Laura
Navarrete, J. M.
Newsome, Phillip N.
Nielsen, Vibeke
Pérez, Martina
Pulido, Juan Manuel Pericas
Piano, Salvatore
Pich, Judit
Escobet, Judit Presas
Pose, Elisa
Lindvig, Katrine Prier
Reichert, Matthias
Riba, Carlota
Roulot, Dominique
Rubio, Ana Belén
Sánchez-Morata, Maria
Schattenberg, Jörn
Serra-Burriel, Feliu
Serra-Burriel, Miquel
Just, Louise Skovborg
Sonneveld, Milan
Soria, Anna
Stern, Christiane
Such, Patricia
Thiele, Maja
Toran, Pere
Torrejón, Antoni
Tonon, Marta
Tsochatzis, Emmanuel A.
van Kleef, Laurens
van Wijngaarden, Paulien
Velázquez, Vanessa
Viu, Ana
Weber, Susanne Nicole
Wildsmith, Tracey
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Innovative Europe (847989)
Instituto de Salud Carlos III (PI18/00862, PI18/01330, PI18/00662)
Agència de Gestió d'Ajuts Universitaris i de Recerca (2017SGR-01281)
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (EHD G020/2022)
Gilead Sciences (IN-ES-989-5309)
- License Information
-
More Information
Article History
Received: 16 June 2022
Accepted: 1 July 2022
First Online: 19 July 2022
Change Date: 22 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12889-023-15867-6
Declarations
:
: This study was approved by the research and ethics board of each participating site, protocol version 1.1 9 January 2018: Comitè d’Ètica d’Investigació Clínica del Hospital Clínic de Barcelona (Spain), Comité de Ética de la Investigación del Hospital Universitari Germans Trias i Pujol (Spain), Comité de Ética de la Investigación Parc de Salut Mar (Spain), Comité de Ética de Investigación del Hospital Universitari Vall d’Hebron (Spain), Comitè d’Ètica d’Investigació IDIAP Jordi Gol (Barcelona), Ethics Board of the University Hospital Dubrava (Croatia), Comité de Protection des Personnes Sud Méditerranée V (France), Comitato Etico per la Sperimentazione Clinica Della Provincicia di Padova (Italy), London-Riverside Research Ethics Committee, NHS Health Research Authority (UK), East Midlands-Derby Research Ethics Committee, NHS Health Research Authority (UK), Ethik-Kommission bei der Landersärztekammer Rheinland-Pfalz, Mainz (Germany), Ethikommission der Ärztekammer des Saarlandes, Saarbrücken (Germany). For Odense Universitetshospital, Denmark, an amendment was made to an ongoing protocol that recruited similar patients and collected the same data as the current project (ethics committee for the Region of Southern Denmark, protocol ID S-20170087). For Erasmus University Medical Center Rotterdam, the need for approval of the protocol was waived due to the fact the center already has multiple studies in progress in “healthy volunteers” in a special research center called ERGO (Erasmus Rotterdam GezondheidsOnderzoek) approved by the Ministry of Health, Welfare and Sport as of December 19, 2016 and as such considered “population screening”.Any changes in the master version of the protocol will be reviewed and approved by all partners and a protocol amendment will be evaluated and approved by each of the Ethics Committee before implemented.Signed informed consent is obtained from all participants.
: Not applicable. The main results of the project will be by the LiverScreen Consortium.
: PG declares he has received Investigator Initiated Research funding from: Gilead, Grifols and Mallinckrodt Pharmaceuticals. He has participated on advisory boards or consultancy for: Gilead, Grifols, Mallinckrodt, Novartis, Martin Pharmaceuticals, and Ferring.LC: Consultancy for Allergan, Alexion, Echosens, Gilead, Intercept, MSD, Novo Nordisk, and Pfizer. Speaker bureau for Abbvie, Echosens, Gilead, Intercept, and Novo Nordisk. Research grant from Gilead.IG: Speaking fees from Gilead, Abbvie, Intercept.MT: Speaking fees from Siemens, Echosens, Norgine; consultancy fee from GE Healthcare.RJK has received Investigator Initiated Research funding from: Gilead, has worked on advisory boards for: AbbVie, BMS, Gilead, Merck, has spoken for AbbVie, Echosens, Gilead, Philips.JMP reports having received consulting fees from Boehringer Ingelheim and Novo Nordisk. He has received speaking fees from Gilead, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898EAT: Consulting fees from Gilead, Intercept, Pfizer and Orphalan.JMS: Consultancy: Boehringer Ingelheim, BMS, Echosens, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Novartis, Novo Nordisk, Nordic Bioscience, Pfizer, Roche, Sanofi, Siemens Healthcare GmbH. Research Funding: Gilead Sciences, Boehringer Ingelheim, Siemens Healthcare GmbH. Speakers Bureau: Falk Foundation MSD Sharp & Dohme GmbH.RMM: Speaker: Gilead, Abbvie, Intercept; Consultant: Intercept, AbbVie.HJdK reports speakers’ fee from MSD on lung cancer screening symposium.AK has served as speaker for Norgine, Siemens and Nordic Bioscience and participated in advisory boards for Norgine and Siemens, all outside the submitted work.All other authors have declared no conflicts.
